Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of SAL0120 tablets in chronic kidney disease
CTR20243967Phase 2Active
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SAL0120 in chronic kidney disease (CKD), sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd.. Started Jan 2025; status: active.
02
Drugs
SAL0120
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on CTR20243967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243967.